Ebru Bilir

Ms. Ebru Bilir

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
SESuheyla Ekemen
Suheyla Ekemen
CCCem Comunoglu
Cem Comunoglu
CKCavit Kerem Kayhan
Cavit Kerem Kayhan
EBEbru Bilir
Ebru Bilir
ICIlkay Cavusoglu
Ilkay Cavusoglu
HEHalit Firat Erden
Halit Firat Erden
In women with unexplained infertility (UI) and recurrent in vitro fertilization (IVF) failures, the etiology is often unclear. Endometrial immune perturbations and the use of immune markers associated with these dysregulations are of great interest in the diagnosis and treatment of UI. However, reliable biomarkers and standardized quantification methods are lacking. Here, to address endometrial immune dysregulation in UI patients with recurrent IVF failures, we performed endometrial tissue sampling and immunostaining of CD56 (uNK), CD138, and BCL-6. Of these cases, 57.9% had positive CD56 in the endometrial stroma, while 46.1% had positive BCL-6 in the glandular epithelium, and 14.5% of the cases were found to be positive for CD138. Combined staining rates were 60.5%, 68.4%, and 71.05% for (CD56 or BCL-6), (CD56 or CD138), and (CD56, BCL-6, or CD138), respectively. There was a significant correlation between CD56 and BCL-6 positivity, while CD138 positivity was an independent parameter. After the recommended targeted therapy, pregnancy rates were found to increase from 58.5% to 61.6% and 73.8% in CD56-positive, (CD56- or BCL-6-positive), and (CD56-, BCL-6-, or CD138-positive) cases, respectively. Notably, a retrospective evaluation of digital pathology and light microscopy results showed a significant correlation. This study suggests that the examination of CD56, BCL-6, and CD138 in the same endometrial sample may be an effective method in determining the etiology of UI and reaching an early diagnosis and treatment options. Moreover, digital pathology can be used in the evaluation of CD56 and BCL-6 to provide objective, rapid, and reliable results.

17 September 2025 in Respiratory Medicine Case Reports
Verified
Journal Article
Open access
NUNazlı Zeynep Uslu
Nazlı Zeynep Uslu
MAMustafa Hasan Adleh
Mustafa Hasan Adleh
EBEbru Bilir
Ebru Bilir
FKFahad Al-Deen Kata
Fahad Al-Deen Kata
MBMerih Kalamanoğlu Balcı
Merih Kalamanoğlu Balcı
Even though uncommon, drug-induced interstitial lung disease (DIILD) represents a serious adverse drug reaction. We report a case of a patient with a history of ulcerative colitis who was receiving mesalazine. The patient developed dyspnea, hypoxemia, and respiratory failure accompanied by resting oxygen desaturation. Initial CT imaging revealed bilateral perihilar ground-glass opacities along with focal areas of consolidation. Inflammatory markers were elevated, but procalcitonin levels remained persistently low; sputum cultures and multiplex PCR ruled against an infectious origin. Mesalazine was discontinued, and the patient's respiratory status improved dramatically. Follow-up CT revealed interval resolution of the pulmonary lesions, and a diagnosis of DIILD was clinically established. This case emphasizes the importance of balancing clinical suspicion between steroid-related infectious risk and an uncommon drug reaction. We also identified similar Mesalazine-associated DIILD cases in the literature to demonstrate similar radiologic patterns, onset time, and outcomes.

9 December 2023 in Acibadem Universitesi Saglik Bilimleri Dergisi
Verified
Journal Article
Closed access
SESuheyla Ekemen
Suheyla Ekemen
DŞDavut Şahin
Davut Şahin
STSadik Toprak
Sadik Toprak
EBEbru Bilir
Ebru Bilir
MAMeryem Akbaş
Meryem Akbaş
SESerkan Erkanlı
Serkan Erkanlı
Introduction: Cervical cancer is one of the most common cancers in women. Precancerous lesions of the cervix can be detected with the combined use of smear testing and HPV (Human Papillomavirus) testing. International guidelines have been developed to indicate at what intervals and in which situations the tests should be performed. In this study, we examined the clinical utility of screening tests in patients with histopathologically diagnosed SCC (squamous cell carcinoma) and HSIL. Metods: Between January 2022 and June 2023, 447 patients aged 19-73 years (mean 37) with cervical biopsy results of SCC and HSIL were evaluated for the use of diagnostic tests (PAP smear and HPV test). Results: PAP smears were performed in 98.2% and HPV tests in 39.1% of all cases before histopathologic diagnosis. The most frequently detected high-risk HPV (hrHPV) was type 16. HPV testing significantly decreased with age. HPV testing was not performed in 74.2% of patients aged 51- 60 years and 80.9% of patients over 60 years. Conclusion: These cases the clinical utility and pathologic evaluation of the PAP smear were optimal. However, HPV testing practice was decreasing, especially with age. Cytologic evaluation may be misleading due to age-related hormonal withdrawal, difficulty in obtaining adequate smears, and atrophic changes. Our recommendation is to use HPV testing in all age groups, but especially in the population over 50 years of age, where cytologic difficulties may occur, HPV testing should be performed optimally until 65 years of age.